Supplementary Table 7.
Treatment group compared with placebo/placebo | Days post treatment | P value (unadjusted) | Placebo/placebo mean | Treatment group mean |
---|---|---|---|---|
Placebo/SER-287 weekly | 0 | .769 | 0.330 | 0.329 |
3 | .701 | 0.317 | 0.296 | |
7 | .469 | 0.288 | 0.339 | |
10 | .871 | 0.265 | 0.354 | |
14 | .733 | 0.326 | 0.342 | |
56 | .517 | 0.340 | 0.400 | |
84 | .626 | 0.421 | 0.443 | |
Vancomycin/SER-287 daily | 0 | .003 | 0.330 | 0.865 |
3 | .001 | 0.317 | 0.775 | |
7 | .001 | 0.288 | 0.747 | |
10 | .001 | 0.265 | 0.663 | |
14 | .001 | 0.326 | 0.672 | |
56 | .002 | 0.340 | 0.650 | |
84 | .067 | 0.421 | 0.680 | |
Vancomycin/SER-287 weekly | 0 | .002 | 0.330 | 0.906 |
3 | <.001 | 0.317 | 0.841 | |
7 | <.001 | 0.288 | 0.775 | |
10 | .001 | 0.265 | 0.718 | |
14 | <.001 | 0.326 | 0.654 | |
56 | .001 | 0.340 | 0.601 | |
84 | .092 | 0.421 | 0.606 |
NOTE. β-diversity distance (binary Jaccard) from baseline for subjects in each treatment group at the given time point, compared with placebo. P value indicates 2-sided Mann Whitney U test for the indicated treatment arm compared with placebo. See Supplementary Table 2 for the number of subjects.